ENDEMIK DIDMENA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | - | - | - | 1,535,847 | 2,281,487 | 1,811,734 | 1,004,718 |
| Profit before tax | -290 | -1,618 | -155 | -105 | 10,998 | 81,214 | 13,429 | -46,026 |
| Net profit | -290 | -1,618 | -155 | -105 | 9,643 | 69,011 | 11,399 | -46,026 |
| Equity | 2,648 | 1,030 | 875 | 770 | 30,236 | 97,891 | 109,290 | 63,264 |
| Liabilities | 55 | 60 | 0 | 0 | 335,271 | 638,613 | 224,945 | 239,408 |
| Non-current assets | 0 | 0 | 0 | 0 | 426 | 226 | 5 | 5 |
| Current assets | 2,703 | 1,090 | 882 | 791 | 369,651 | 735,558 | 333,438 | 301,936 |
| Total assets | 2,703 | 1,090 | 882 | 791 | 370,077 | 735,784 | 333,443 | 301,941 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 30,473 | 15,906 | 11,508 |
| Social insurance contributions | - | - | - | - | - | 12,733 | 17,478 | 13,099 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | - | - | - | +48.5% | -20.6% | -44.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -10.7% | -148.4% | -17.6% | -13.3% | 2.6% | 9.4% | 3.4% | -15.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -11.0% | -157.1% | -17.7% | -13.6% | 31.9% | 70.5% | 10.4% | -72.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | 0.6% | 3.0% | 0.6% | -4.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | 0.7% | 3.6% | 0.7% | -4.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.1 | - | - | 11.1 | 6.5 | 2.1 | 3.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | 383,962 | 456,297 | 374,844 | 169,811 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
ENDEMIK DIDMENA - Social security debts
The company had no debts to Sodra
ENDEMIK DIDMENA - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
ENDEMIK DIDMENA, UAB (code 302244593) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €1.00M, down 44.5% year on year and 56.0% over two years, showing a clear contraction from €2.28M in 2023 and €1.81M in 2024. Profitability also weakened materially: net profit fell from €69.0K in 2023 to €11.4K in 2024, before turning into a €46.0K net loss in 2025, with the profit margin moving from 3.0% to 0.6% and then to -4.6%. The balance sheet also softened, with total assets declining to €301.9K in 2025 from €333.4K in 2024 and €735.8K in 2023. Equity stood at €63.3K, liabilities at €239.4K, and the equity ratio was 20.9%. The debt-to-equity ratio was 3.78, asset turnover 3.33x, ROA -15.2%, and ROE -72.8%. Revenue per employee was €200.9K, while profit per employee was -€9.2K.